Latest Multi-drug-resistant tuberculosis Stories
MOSCOW, February 13, 2014 /PRNewswire/ -- Russian and Korean biotech companies Infectex Ltd. [http://www.infectex.ru/?ln=en ] and Qurient Ltd.
Aim to Improve Care for HIV Patients in Irkutsk, Halt Growing Health Threat Charlottesville, VA (PRWEB) January 28, 2014 Researchers at the University
Research led by St.
Immunitor, Inc., a commercial stage company committed to developing oral therapeutic vaccines, today announced that its second Phase II trial of oral TB vaccine with heat-killed Mycobacterium
Lauds Reduction in New Infections and Lowered Mortality Rate of TB; Urges More Aggressive Identification of Nearly 3 Million “Missed” New Cases of TB Annually and Greater Focus on More Virulent
Immunitor company announces publication of a successful clinical trial in 43 patients with tuberculosis who were given daily pill of therapeutic vaccine containing heat-killed Mycobacterium vaccae.
Virtual observation of patients taking their prescribed TB medication, could prove an effective technique for ensuring patients effectively complete their course of treatment.
Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.
A new study has calculated the average cost per case of TB in the EU.
- A serpent whose bite was fabled to produce intense thirst.